Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

In a report released today, Sean McGowan from Roth MKM maintained a Buy rating on Niagen Bioscience, with a price target of $23.00. According to Ti...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NAGE	$6.52	-1.66%	710.32K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NAGE	$6.52	-1.7%	710.32K
3
4
5
6

NAGE

NAGE

Get NA Data in Excel

Get NA Data in Excel